Sanara MedTech Inc. (SMTI)
| Market Cap | 317.63M +5.1% |
| Revenue (ttm) | 109.81M +13.0% |
| Net Income | -32.01M |
| EPS | -3.69 |
| Shares Out | 9.19M |
| PE Ratio | n/a |
| Forward PE | 103.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 344,468 |
| Open | 34.46 |
| Previous Close | 34.58 |
| Day's Range | 34.46 - 34.76 |
| 52-Week Range | 16.05 - 35.95 |
| Beta | 1.16 |
| Analysts | Hold |
| Price Target | 35.00 (+1.24%) |
| Earnings Date | Aug 11, 2026 |
About SMTI
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-... [Read more]
Financial Performance
In 2025, Sanara MedTech's revenue was $103.12 million, an increase of 18.97% compared to the previous year's $86.67 million. Losses were -$37.56 million, 288.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SMTI stock is "Hold." The 12-month stock price target is $35.0, which is an increase of 1.24% from the latest price.
News
MiMedx price target raised to $8 from $6 at Craig-Hallum
Craig-Hallum raised the firm’s price target on MiMedx (MDXG) to $8 from $6 and keeps a Buy rating on the shares. The pending acquisition of Sanara MedTech (SMTI) gives the…
Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)
FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developin...
Sanara MedTech Earnings release: Q2 2026
Sanara MedTech released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Sanara MedTech Quarterly report: Q2 2026
Sanara MedTech has published its Q2 2026 quarterly earnings report on August 11, 2026.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Sanara MedTech downgraded to Hold from Buy at Freedom Broker
Freedom Broker downgraded Sanara MedTech (SMTI) to Hold from Buy with an unchanged price target of $35. The firm says the $35 per share acquisition of Sanara by Mimedx validates…
Sanara MedTech downgraded to Hold from Buy at Lake Street
Lake Street downgraded Sanara MedTech (SMTI) to Hold from Buy with a price target of $35, up from $32, after MiMedx (MDXG) announced it will acquire Sanara for $35 per…
Sanara MedTech downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Sanara MedTech (SMTI) to Neutral from Buy with a price target of $35, down from $36, after the company entered into a merger agreement under which MiMedx…
MiMedx to acquire Sanara MedTech for $35 per share, $350M enterprise value
MiMedx Group (MDXG) and Sanara MedTech (SMTI) announced that they have entered into a definitive merger agreement under which MiMedx will acquire all of the outstanding shares of Sanara in…
Sanara Medtech Inc trading resumes
16:30 EDT Sanara Medtech (SMTI) Inc trading resumes
MIMEDX to Acquire Sanara MedTech
Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX's Strategic Priority to Expand Surgical Footprint, Nearly Doubli...
Sanara Medtech Inc trading halted, news pending
14:21 EDT Sanara Medtech (SMTI) Inc trading halted, news pending
Sanara MedTech initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of Sanara MedTech (SMTI) with a Buy rating and $35 price target Sanara develops and commercializing products for surgical wound and soft tissue management, the analys...
Sanara MedTech management to meet with Lake Street
Meeting to be held in New York on June 9 hosted by Lake Street.
Sanara MedTech Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and advisory votes on executive compensation and its voting frequency. All proposals passed, with directors elected, auditor ratified, compensation approved, and a three-year advisory vote frequency set.
Sanara MedTech Slides: Investor presentation
Sanara MedTech has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Sanara MedTech reports Q1 EPS 4c vs. (7c) last year
Last night, the company also reported Q1 revenue $27.8M vs. $23.4M last year. Seth Yon, CEO, commented, “The first quarter of 2026 is the first full quarter in which the…
Sanara MedTech Earnings Call Transcript: Q1 2026
Q1 2026 delivered 19% revenue growth and a return to GAAP net profitability, driven by strong sales of core surgical products and expanded market presence. Guidance for 2026 was reaffirmed, with continued investment in sales and R&D supporting long-term growth.
Sanara MedTech Earnings release: Q1 2026
Sanara MedTech released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Sanara MedTech Quarterly report: Q1 2026
Sanara MedTech has published its Q1 2026 quarterly earnings report on May 12, 2026.
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter
Sanara MedTech Proxy statement: Proxy filing
Sanara MedTech filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Sanara MedTech Proxy statement: Proxy filing
Sanara MedTech filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Sanara MedTech Proxy statement: Proxy filing
Sanara MedTech filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Sanara MedTech initiated with a Buy at Lake Street
Lake Street initiated coverage of Sanara MedTech (SMTI) with a Buy rating and $32 price target The firm, which estimates Sanara generates $116M of revenue with 14% AEBITDA margins for…